It would be a revolution for patients.

Chemotherapy could become much simpler for cancer patients.

A French study opens the way to a subcutaneous injection protocol, and no longer intravenously as today, but the process has yet to prove itself in humans.

Cancer treatment is very often based on the administration of chemotherapy intravenously, which generates a lot of constraints and requires hospitalization.

A study, conducted in France on animals and published by the

Journal of the American Chemical Society

, opens up hope for a simplified procedure.

Better efficiency?

One of the possibilities envisaged to lighten the current protocol is indeed chemotherapy by the subcutaneous route.

Much simpler to implement and more comfortable for the patient, it is nevertheless impossible to practice most of the time, because the active ingredients are aggressive and tend to stagnate at the level of the subcutaneous tissue where they cause necrosis of the skin. skin because of their high toxicity.

To circumvent this obstacle, scientists have developed a new approach: by coupling a sparingly soluble and aggressive active ingredient widely used in chemotherapy, paclitaxel, with a polymer having a very strong affinity with water, they have succeeded in obtaining an anticancer soluble, thus being able to pass rapidly from the subcutaneous tissue into the bloodstream, without causing toxicity at the site where it is administered.

During the preclinical development of this new chemotherapy in mice, they were even able to obtain better efficacy than with the commercial formulation of the active ingredient (Taxol) administered intravenously.

Increase patient comfort

“Chemotherapy has a lot of logistical constraints (requiring qualified personnel, hospitalizations, etc.), a high cost.

The main interest of this new approach would be to facilitate chemotherapy and increase the comfort of patients, who could perhaps receive it at home,” explained Julien Nicolas, research director at the French National Center for Scientific Research (CNRS). ) and lead author of the study.



Although this research has yielded promising results in an animal model, it has yet to prove its effectiveness in humans.

This is why scientists have created a start-up, Imescia, and hope to be able to start a clinical trial in 2024.

Health

Childhood cancer: An innovative treatment for the pain of a side effect of chemo

Health

Occupational cancers: ANSES proposes including 18 cancer drugs in the list of carcinogenic processes

  • Chemotherapy

  • Cancer

  • study

  • Scientists

  • Health